ERYKINE

Erykine 40000IU injection contains Recombinant human erythropoietin alfa/epoetin alfa as its active component, and it belongs to a class of drugs known as erythropoiesis-stimulating agents (ESAs). This medication is primarily used to treat anemia that arises from various underlying conditions, including chronic kidney disease (CKD), certain types of cancer chemotherapy, or treatment for HIV infection with zidovudine. Furthermore, it helps to reduce the need for red blood cell transfusions in patients who face a high risk of significant blood loss due to planned surgical procedures or other medical interventions.

However, Erykine 40000IU injection is not suitable for all patients. It should not be used in individuals with a known hypersensitivity to the injection or any of its components, uncontrolled hypertension (high blood pressure), active thrombotic microangiopathy (TMA), pure red cell aplasia (PRCA), uncontrolled seizures, or during pregnancy or lactation. Caution is also advised when using this medication in patients with a history of blood clots, heart disease, stroke, kidney disease, liver disease, thalassemia, sickle cell anemia, myelodysplastic syndrome, leukemia, or cancer. For children under 18, it should only be used if the potential benefits clearly outweigh the risks. Older adults receiving this medication require close monitoring for any adverse side effects. Before initiating treatment with Erykine 40000IU injection, it is crucial to have a thorough discussion with your doctor about its potential risks and benefits